Personal information

Drug Discovery, Medicinal Chemistry, Synthetic Organic Chemistry, Heart Disease, Antibiotics, CRO, Medicine, Psychology

Biography

I received a Ph.D. in chemistry in 1991 from the Freie Universität Berlin, inventing with Prof. J. Mulzer the Cr(II) mediated addition of chiral allyl bromides to aldehydes (Hiyama-reaction) and applied this method in natural product synthesis. In the course of a postdoctoral study from 1991 to 1993 at the medicinal chemistry department of Hoffmann-La Roche, Nutley, NJ, USA with Dr. M. Uskokovic, I invented a new method for the synthesis of vitamin D metabolites and steroids by a stereoselective Pausen-Khand-reaction. In 1993 I joined the pharmaceutical chemistry department of the Universität des Saarlandes (Prof. R. Hartmann), where I was involved with the development of new 5-α reductase inhibitors considered as potential drugs against hormone mediated prostate cancer. Before founding the CRO Endotherm, I was appointed as a senior consultant in a consultancy company in Düsseldorf, where I was involved with public fundraising for medium sized enterprises.

Activities

Employment (3)

Endotherm GmbH: Saarbruecken, Saarland, DE

1999 to present | CEO
Employment
Source: Self-asserted source
Lars Kattner

Universität des Saarlandes: Saarbrücken, Saarland, DE

1994 to 1996 | Postdoc (Pharmaceutical Chemistry and Institute for New Materials)
Employment
Source: Self-asserted source
Lars Kattner

Hoffmann-La Roche: Nutley, New Jersey, US

1991 to 1993 | Research Associate (Medicinal Chemistry)
Employment
Source: Self-asserted source
Lars Kattner

Professional activities (8)

Société de Chimie Thérapeutique: Chatenay-Malabry, FR

Membership
Source: Self-asserted source
Lars Kattner

International Isotope Society Central European Division e.V.: Wuppertal, DE

2019 to present (International Isotope Society)
Membership
Source: Self-asserted source
Lars Kattner

American Association for the Advancement of Science: DC, DC, US

2018 to present
Service
Source: Self-asserted source
Lars Kattner

American Association for Clinical Chemistry: Washington, DC, US

2015 to present
Membership
Source: Self-asserted source
Lars Kattner

Euroean Federation of Biotechnology: Bacelona, ES

2006 to present
Membership
Source: Self-asserted source
Lars Kattner

American Chemical Society: Washington, DC, US

2003 to present
Service
Source: Self-asserted source
Lars Kattner

Gesellschaft Deutscher Chemiker eV: Frankfurt am Main, Hessen, DE

1988 to present
Membership
Source: Self-asserted source
Lars Kattner

Universidad de Santiago de Compostela Departamento de Química Orgánica: Santiago De Compostela, Galicia, ES

2015-08-08 to 2015-09-08 | Guest Scientist (Departamento de Quimica Organica)
Invited position
Source: Self-asserted source
Lars Kattner

Funding (5)

Development of a novel allosteric modulator to treat post-traumatic stress disorder

2019-10 to 2022-09 | Grant
Bundesministerium für Bildung und Forschung (Bonn, NRW, DE)
Part of GRANT_NUMBER: 01QE1930
Source: Self-asserted source
Lars Kattner

A novel therapeutic drug for the treatment of polycystic kidney disease

2018-12 to 2021-11 | Grant
Bundesministerium für Bildung und Forschung (Bonn, NRW, DE)
Part of GRANT_NUMBER: 01QE1857
Source: Self-asserted source
Lars Kattner

EUTrigTreat

2009 to 2014 | Grant
EU Commission (Brussels, EU, DE)
Source: Self-asserted source
Lars Kattner

Design und synthesis of novel inhibitors of MurA, an antibacterial target enzyme

2008 to 2010 | Grant
Bundesministerium für Wirtschaft und Energie (Berlin, DE)
Source: Self-asserted source
Lars Kattner

EUGeneHeart

2007-06 to 2010-06 | Grant
European Commission (Brussels, DE)
GRANT_NUMBER:

LSHM-CT-2005-018833

Source: Self-asserted source
Lars Kattner

Works (20)

Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry

Journal of Medicinal Chemistry
2020-12-10 | Journal article
Contributors: Patrick Mäder; Lars Kattner
Source: check_circle
Crossref

Highly regio- and stereoselective hydroxylation of vitamin D2 by CYP109E1

Biochemical and Biophysical Research Communications
2020-04 | Journal article
Contributors: Natalia Putkaradze; Lisa König; Lars Kattner; Michael C. Hutter; Rita Bernhardt
Source: check_circle
Crossref

Sarcoplasmic reticulum calcium leak contributes to arrhythmia but not to heart failure progression

Science Translational Medicine
2018-09-12 | Journal article
Contributors: Belal A. Mohamed; Nico Hartmann; Petros Tirilomis; Karolina Sekeres; Wener Li; Stefan Neef; Claudia Richter; Elisabeth M. Zeisberg; Lars Kattner; Michael Didié et al.
Source: check_circle
Crossref

An efficient synthesis of 1,25-dihydroxyvitamin D3 LC-biotin

J Steroid Biochem Mol Biol
2017 | Journal article
Source: Self-asserted source
Lars Kattner

Synthesis of low abundant vitamin D metabolites and assaying their distribution in human serum by liquid chromatography-tandem mass spectrometry (LC-MS/MS) as a new tool for diagnosis and risk prediction of vitamin D related diseases

2017 | Book chapter
Source: Self-asserted source
Lars Kattner

The relevant role of SR Ca leak in the development of heart failure.

2017 | Conference paper
Source: Self-asserted source
Lars Kattner

Optimization of chemical syntheses of vitamin D C3-epimers

Anticancer Res.
2016 | Journal article
Source: Self-asserted source
Lars Kattner

Development of efficient chemical syntheses of vitamin D degradation products

Anticancer Res.
2015 | Journal article
Source: Self-asserted source
Lars Kattner

Synthetic retinal analogues modify the spectral and kinetic characteristics of microbial rhodopsin optogenetic tools

nature communications
2014 | Journal article
Source: Self-asserted source
Lars Kattner

Chemical, Biochemical and Microbiological Properties of a Brominated Nitrovinylfuran with Broad-Spectrum Antibacterial Activity

Bioorganic & Medicinal Chemistry
2013 | Journal article
Source: Self-asserted source
Lars Kattner

Combined Na+/Ca2+ Exchanger and L-Type Calcium Channel Block as a Potential Strategy to Suppress Arrhythmias and Maintain Ventricular Function

Circ Arrhythm Electrophysiol.
2013 | Journal article
Source: Self-asserted source
Lars Kattner

Development of a Colorimetric and a Fluorescence Phosphatase-Inhibitor Assay Suitable for Drug Discovery Approaches

J Biomol Screen
2013 | Journal article
Source: Self-asserted source
Lars Kattner

Colorimetric protein phosphatase inhibition assay for specific detection of phosphatase-inhibitor-1 inhibitory compounds

Naunyn Schmiedebergs Arch Pharmakol.
2009 | Journal article
Source: Self-asserted source
Lars Kattner

Optimization of assay Conditions for Dengue Virus protease. Effect of various Polyols and Nonionic Detergents

J. Biomol Screen
2009 | Journal article
Source: Self-asserted source
Lars Kattner

Identification of Terfenadine as an Inhibitor of Human CD81-receptor HCV-E2 Interaction: Synthesis and Structure Optimization

2008 | Journal article
Source: Self-asserted source
Lars Kattner

Outsourcing of medicinal chemistry in the drug discovery process faces CRO´s and pharmaceutical companies with challenges

PharmChem.
2007 | Journal article
Source: Self-asserted source
Lars Kattner

A mechanistic study of the Hiyama-Nozaki allylation: evidence for radical intermediates

Tetrahedron Lett.
2004 | Journal article
Source: Self-asserted source
Lars Kattner

Synthesis and Biochemical Evaluation of Carbamoyl-Phenyloxy Carboxylic Acid Derivatives as Nonsteroidal 5a-Reductase Inhibitors

Arch. Pharm.
1995 | Journal article
Source: Self-asserted source
Lars Kattner

Highly Felkin-Anh Selective Hiyama Additions of Chiral Allylic Bromides to Aldehydes; Application to the First Synthesis of Nephromopsinic Acid and Ist Enantiomer;

J. Am. Chem. Soc.
1991 | Journal article
Source: Self-asserted source
Lars Kattner

Doubly Stereodifferantiating Hiyama Addition with Mismatched Reactants; Enantio- and Diastereocontrolled Synthesis of Dihydrocanadensolide

Angew. Chem. Int. Ed. Engl.
1990 | Journal article
Source: Self-asserted source
Lars Kattner

Peer review (3 reviews for 3 publications/grants)

Review activity for ACS medicinal chemistry letters. (1)
Review activity for Journal of medicinal chemistry. (1)
Review activity for Journal of organic chemistry. (1)